SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of Earliest Event Reported) January 27, 1999
E. I. du Pont de Nemours and Company
(Exact Name of Registrant as Specified in Its Charter)
Delaware 1-815 51-0014090
(State or Other Jurisdiction (Commission (I.R.S Employer
of Incorporation) File Number) Identification No.)
1007 Market Street
Wilmington, Delaware 19898
(Address of principal executive offices)
Registrant's telephone number, including area code: (302) 774-1000
1
<PAGE>
Item 7. Financial Statements and Exhibits
---------------------------------
In connection with Debt and/or Equity Securities that may be offered
on a delayed or continuous basis under Registration Statements on Form S-3
(No. 33-53327, No. 33-61339 and No. 33-60069), we hereby file the following
press release.
Exhibit
Number Description of Exhibit
------- -------------------------------------------------
99 Copy of the Registrant's Earnings Press Release,
dated January 27, 1999.
2
<PAGE>
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
E. I. DU PONT DE NEMOURS AND COMPANY
(Registrant)
/s/D. B. Smith
------------------------------------
D. B. Smith
Assistant Controller
January 27, 1999
3
<PAGE>
EXHIBIT INDEX
Exhibit
Number Description of Exhibits
- ------- ------------------------------------------------------------
99 Copy of the Registrant's Earnings Press Release, dated
January 27, 1999.
4
<PAGE>
EXHIBIT 99
Contact: Susan Gaffney
(302) 774-2698
DUPONT REPORTS FOURTH QUARTER AND FULL YEAR 1998 EARNINGS
---------------------------------------------------------
Wilmington, Del., Jan., 27 -- DuPont reported fourth
quarter diluted earnings per share from continuing operations
before nonrecurring items of $.60, down 8 percent versus the
fourth quarter 1997 but 13 percent above the third quarter 1998.
For the full year 1998, diluted earnings per share from
continuing operations before nonrecurring items were $2.55 per
share, down 6 percent versus a record $2.70 in 1997. Including
discontinued operations, diluted earnings per share before
nonrecurring and extraordinary items for the fourth quarter and
the full year were $.61 and $3.07, respectively.
UNDERLYING EARNINGS COMPARISONS
-------------------------------
4th 4th
Quarter Quarter Full Year Full Year
(per share diluted) 1998 1997 1998 1997
------- ------- --------- ---------
Continuing Operations $.60 $.65 $2.55 $2.70
Discontinued Operations .01 .18 .52 .85
---- ---- ----- -----
Total $.61 $.83 $3.07 $3.55
==== ==== ===== =====
4th Quarter Highlights
- ----------------------
o Recorded the second highest ever underlying after-tax
operating income from continuing operations for a fourth
quarter.
o Completed divestiture of 30 percent of the Company's
interest in Conoco via a $4.2 billion initial public
offering.
o Completed sale of substantially all the Company's
remaining interest in coal operations.
o Announced agreement to purchase Hoechst AG's automotive
coatings business (Herberts) for DM 3.1 billion
(approximately $1.9 billion.)
5
<PAGE>
"Despite a challenging economic environment in which
DuPont faced continued downward pressure on selling prices and a
$.15 per share negative currency impact, underlying earnings of
$2.55 per share from continuing operations for the year were only
6 percent below 1997," said DuPont Chairman and Chief Executive
Officer Charles O. Holliday, Jr. "After four years of record
earnings, we are disappointed by these results but not dis-
couraged for the future. In this environment almost half of our
business units successfully increased their earnings year over
year."
Holliday added, "Our view of the global economy suggests
several more quarters of low volume growth and continued price
pressure. We are responding to these market challenges and
developing appropriate opportunities. Lower raw material costs
and more favorable currency comparisons, combined with results
from our productivity focus should all contribute to our ability
to weather this cycle more favorably than in the past."
Reported Earnings - Including Nonrecurring Items
- ------------------------------------------------
Fourth quarter diluted earnings from continuing opera-
tions including nonrecurring items were $.68 per share compared
to $.06 per share in 1997. The current quarter includes non-
recurring items as detailed in the accompanying footnotes total-
ing a net benefit of $.08 per share. The fourth quarter 1997
included nonrecurring charges totaling $.59 per share, princi-
pally the write-off of in-process R&D related to acquisitions.
6
<PAGE>
Including nonrecurring items, diluted earnings from
discontinued operations for the fourth quarter were $2.14 per
share compared to $.17 per share for the fourth quarter 1997.
The current quarter includes a net nonrecurring gain of $2.13 per
share, principally reflecting a gain from the issuance of stock
in the Conoco IPO. Fourth quarter 1997 included a $.01 net
charge for nonrecurring items.
Total Company earnings including the nonrecurring items
described above were $2.82 per share for the fourth quarter and
$3.90 for the year, compared to $.23 and $2.08 per share,
respectively, earned in 1997.
DILUTED EARNINGS ($) PER SHARE
------------------------------
4th 4th
Quarter Quarter Full Year Full Year
1998 1997 1998 1997
------- ------- --------- ---------
Continuing Operations
- ---------------------
Underlying $ .60 $.65 $2.55 $2.70
Reported .68 .06 1.43 1.24
Discontinued Operations
- -----------------------
Underlying .01 .18 .52 .85
Reported 2.14 .17 2.65 .84
Extraordinary Item -- -- (.18) --
- ------------------
Total Company
- -------------
Underlying* .61 .83 3.07 3.55
Reported 2.82 .23 3.90** 2.08
- --------------------
*Includes per share amounts from discontinued operations.
**Includes 3Q98 extraordinary charge of $.18 per share for early
redemption of debt.
7
<PAGE>
Results From Continuing Operations
- ----------------------------------
For the year, sales were $24.8 billion, up 3 percent from
$24.1 billion in 1997. Sales from acquisitions added roundly
$2.1 billion or 9 percent. After-tax operating income from
continuing operations before nonrecurring items for the year 1998
was $3.2 billion versus $3.3 billion in 1997.
Segment Analysis
----------------
The following compares the full year 1998 with prior
year for segment results from continuing operations before
nonrecurring items described in the accompanying footnotes.
Chemicals segment earnings were $662 million compared
with $590 million earned last year, up 12 percent, principally
due to higher earnings from white pigments. Segment sales of
$4.1 billion were 4 percent lower, reflecting an 8 percent
decline from lower sales volume and divested hydrogen peroxide
production. Segment selling prices were up 4 percent prin-
cipally reflecting higher white pigment prices.
Fibers segment earnings were $843 million, 12 percent
below the $962 million earned in 1997. This principally
reflects lower "Dacron" polyester and "Lycra" spandex earnings.
"Dacron" polyester had significant declines in volume and
selling prices resulting from competitive pressures and imports.
"Lycra" spandex results were principally affected by weakness in
Europe. Segment sales of $7.3 billion were down 5 percent as
selling prices averaged 3 percent lower and sales volumes
2 percent lower.
8
<PAGE>
Earnings for the polymers segment were $925 million,
up 2 percent from the $911 million earned in 1997, reflecting
improved results from engineering polymers and fluoropolymers,
offset by lower earnings from automotive products. Segment
sales of $6.9 billion, sales volume, and selling prices were
flat versus 1997.
Life Sciences segment earnings were $500 million, down
17 percent from $603 million in 1997. Pharmaceuticals earnings
were 15 percent higher reflecting higher ownership in the second
half due to the buy out of Merck's interest in DuPont Merck
Pharmaceuticals, improved results from "Coumadin" warfarin
sodium and the successful launch of SustivaTM, a new drug for
the treatment of HIV and AIDS. Agricultural Products earnings
were 29 percent lower, reflecting lower worldwide prices and
lower U.S. volumes for crop protection products. Segment sales
of $3.4 billion were up 33 percent reflecting $1.2 billion of
additional revenue from acquisitions (principally pharmaceu-
ticals).
Diversified businesses earnings were $275 million, up
3 percent from $268 million in 1997. This reflects the absence
of losses incurred last year from the now divested printing and
publishing business, partly offset by earnings declines in the
polyester related businesses. Segment sales were $3.2 billion,
up 13 percent from $2.8 billion in 1997. This reflects addi-
tional sales from acquired businesses, partly offset by absence
of sales of divested businesses and 6 percent lower prices.
9
<PAGE>
Results From Discontinued Operations
- ------------------------------------
For the year 1998, income from discontinued operations
before nonrecurring items was $608 million after tax, down
38 percent from $979 million in 1997. This decline is princi-
pally attributable to lower worldwide oil and gas prices.
Please refer to the press release issued by Conoco today for
additional information and perspective regarding its operations.
Income from discontinued operations including nonrecurring items
was $3,033 million for the year 1998, compared to $973 million
in 1997.
###
Forward-Looking Statements: This release contains
forward-looking statements relating to DuPont's operations that
are based on management's current expectations, estimates and
projections. These statements are identified by words such as
"looking ahead," "expects," "anticipates," "plans," "intends,"
"projects," "indicates," and similar expressions. These
statements are not guarantees of future performance and involve
a number of risks, uncertainties and assumptions that could
cause actual results to differ materially, as discussed more
fully elsewhere in this release and in DuPont's filings with the
Securities and Exchange Commission, particularly its Current
Report on Form 8-K filed on November 13, 1998.
1/27/99
10
<PAGE>
<TABLE>
E. I. DU PONT DE NEMOURS AND COMPANY AND CONSOLIDATED SUBSIDIARIES
<CAPTION>
Three Months Ended Year Ended
CONSOLIDATED INCOME STATEMENT<Fa> December 31 December 31
- ----------------------------------------------------------------------------------------------------------------------
(Dollars in millions, except per share) 1998 1997 1998 1997
- ---------------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C>
SALES ............................................................. $ 6,099 $ 5,903 $24,767 $24,089
Other Income<Fb> .................................................. 356 169 981 1,005
------- ------- ------- -------
Total ......................................................... 6,455 6,072 25,748 25,094
------- ------- ------- -------
Cost of Goods Sold and Other Expenses ............................. 4,196 4,216 16,972 16,636
Selling, General and Administrative Expenses ...................... 588 534 2,115 2,061
Depreciation and Amortization ..................................... 385 346 1,452 1,361
Interest Expense .................................................. 104 121 520 389
Purchased In-Process Research and Development<Fc> ................. (58) 628 1,443 1,478
Employee Separation Costs and Write-Down of Assets<Fd> ............ 56 - 633 340
------- ------- ------- -------
Total ......................................................... 5,271 5,845 23,135 22,265
------- ------- ------- -------
INCOME FROM CONTINUING OPERATIONS BEFORE INCOME TAXES AND
MINORITY INTERESTS .............................................. 1,184 227 2,613 2,829
Provision for Income Tax Expenses ................................. 398 147<Fc> 941 1,354<Fc>
Minority Interests in Earnings of Consolidated Subsidiaries ....... 5 9 24 43
------- ------- ------- -------
INCOME FROM CONTINUING OPERATIONS ................................. 781 71 1,648 1,432
DISCONTINUED OPERATIONS
Income from Operations of Discontinued Business, Net of Income
Taxes<Fa> ..................................................... - 191 594 973
Gain on Disposal of Discontinued Business, Net of Income
Taxes<Fa> ..................................................... 2,439 - 2,439 -
------- ------- ------- -------
INCOME BEFORE EXTRAORDINARY ITEM .................................. 3,220 262 4,681 2,405
Extraordinary Charge From Early Extinguishment of Debt, Net of
Income Taxes<Fe> ................................................ - - (201) -
------- ------- ------- -------
NET INCOME ........................................................ $ 3,220 $ 262 $ 4,480 $ 2,405
======= ======= ======= =======
BASIC EARNINGS PER SHARE OF COMMON STOCK<Ff>
Continuing Operations ........................................... $ .69 $ .06 $ 1.45 $ 1.26<Fg>
Discontinued Operations ......................................... 2.17 .17 2.69<Fg> .86<Fg>
Extraordinary Charge ............................................ - - (.18) -
------- ------- ------- -------
Net Income ...................................................... $ 2.86 $ .23 $ 3.96<Fg> $ 2.12
======= ======= ======= =======
DILUTED EARNINGS PER SHARE OF COMMON STOCK<Ff>
Continuing Operations ........................................... $ .68 $ .06 $ 1.43<Fg> $ 1.24
Discontinued Operations ......................................... 2.14 .17 2.65<Fg> .84<Fg>
Extraordinary Charge ............................................ - - (.18) -
------- ------- ------- -------
Net Income ...................................................... $ 2.82 $ .23 $ 3.90 $ 2.08<Fg>
======= ======= ======= =======
DIVIDENDS PER SHARE OF COMMON STOCK $ .35 $ .315 $ 1.365 $ 1.23
======= ======= ======= =======
</TABLE>
11
<PAGE>
[FN]
NOTES TO CONSOLIDATED INCOME STATEMENT
- --------------------------------------
<Fa> Discontinued Operations:
On September 28, 1998, the Company's Board of Directors approved a
plan to divest the Company's wholly owned petroleum business
(Conoco). On October 21, 1998, Conoco sold, in an initial public
offering (IPO), 191,456,427 shares of Conoco Class A common stock at
$23.00 per share for net proceeds of $4,228. The Company intends to
complete the divestiture with a tax-free split off of its remaining
Conoco shares (69.5%) to DuPont shareholders no later than third
quarter 1999. The Company has not recognized a deferred tax
liability for the difference between the book basis and tax basis of
its investment in Conoco's common stock because the Company does not
expect this basis difference to become subject to tax. The
Company's consolidated financial statements and notes report its
petroleum business as Discontinued Operations. Prior periods have
been restated. Fourth quarter results reported by Conoco to its
shareholders are on a standalone basis and differ from results based
on discontinued operations reporting as discussed below.
Income from Operations of Discontinued Business reflects income
taxes of $267, $311, and $921 for the three months ended
December 31, 1997 and for the years ended December 31, 1998 and
1997, respectively. The fourth quarter 1997 and year ended
December 31, 1997 include charges of $112 for impairment of non-
revenue producing properties and $55 for a write-down of an office
building held for sale, substantially offset by a $161 gain on the
sale of certain North Sea producing and exploration properties.
Effective October 1, 1998, Conoco's results are reported as part of
Gain on Disposal of Discontinued Business. For the three months
ended December 31, 1998, such gain is $2,439. This includes a loss
from Conoco's operations of $148 (after a tax benefit of $116 and a
minority interest benefit of $45). This loss includes nonrecurring
charges of $164: $127 for compensation expense for options granted
by Conoco in substitution for DuPont options held by Conoco
employees, $69 for employee separation costs and property impair-
ments, partially offset by $32 of asset sales.
<Fb> Fourth quarter 1998 includes a $217 gain on the sale of substan-
tially all of the Company's remaining interest in CONSOL Energy Inc.
Also, effective July 1, 1998, Other Income no longer reflects equity
affiliate earnings from The DuPont Merck Pharmaceutical Co. (DuPont
Merck) as these results are now fully consolidated due to the
purchase of Merck's 50% interest in DuPont Merck.
Total year 1997 includes a benefit of $115 from the Company's equity
interest in the gain on the sale by The DuPont Merck Pharmaceutical
Co. (now DuPont Pharmaceuticals) of its generic and multisource
product lines.
12
<PAGE>
[FN]
NOTES TO CONSOLIDATED INCOME STATEMENT - (CONT'D)
- --------------------------------------
<Fc> Purchased In-Process Research and Development represents the value
assigned in a purchase business combination to research and
development projects of the acquired business that were commenced
but not yet completed at the date of acquisition, for which tech-
nological feasibility has not been established and which have no
alternative future use in research and development activities or
otherwise.
The fourth quarter 1998 net benefit represents adjustments, based on
revision of preliminary purchase price allocations to purchased
in-process research and development, in conjunction with 1) the
purchase of Merck's 50% interest in The DuPont Merck Pharmaceutical
Company (reduction of $70) and 2) the purchase of the ICI polyester
businesses (increase of $12).
Total year 1998 includes $1,230 for DuPont Pharmaceuticals, $153 for
the polyester businesses and $60 to increase, based on revision of
preliminary purchase price allocations, the $500 charge taken in the
fourth quarter 1997 in connection with the purchase of Protein
Technologies International (PTI).
Fourth quarter 1997 represents the $500 charge for PTI based on
preliminary allocations of purchase price (indicated above), a
charge of $53, based on revision of preliminary purchase price
allocations in conjunction with the purchase of a 20 percent
interest in Pioneer Hi-Bred International, Inc. (Pioneer) and a
charge of $75, based on preliminary allocations of purchase price,
in conjunction with the purchase of the ICI polyester businesses.
Total year 1997 includes a charge of $903 for Pioneer, and the
fourth quarter 1997 charges of $500 for PTI and $75 for the ICI
polyester businesses as discussed above. The charges associated
with Pioneer and PTI were not tax effected because these trans-
actions were stock acquisitions rather than asset purchases.
<Fd> Fourth quarter 1998 includes a $56 impairment write-down to fair
value of certain Pharmaceuticals assets.
In addition, total year 1998 includes $391 resulting from the
implementation of Company-wide productivity improvement initiatives
($202 associated with separation costs for over 2,600 employees and
$189 in asset write-downs, principally due to shutdown and disman-
tlement of excess production capacity); $108 of employee separation
costs and $78 for the shutdown of related manufacturing facilities
within the Nylon business.
1997 represents charges, primarily write-downs, associated with
exiting the Company's global graphic arts films and offset printing
plates businesses.
13
<PAGE>
[FN]
NOTES TO CONSOLIDATED INCOME STATEMENT - (CONT'D)
- --------------------------------------
<Fe> During 1998, the Company recognized an extraordinary after-tax
charge of $201 ($275 pretax, less taxes of $74) for the early
extinguishment of debt with an aggregate principal amount of $1,633.
<Ff> Earnings per share are calculated on the basis of the following
average number of common shares outstanding:
Three Months Ended Year Ended
December 31 December 31
----------------------------- ----------------------------
Basic Diluted Basic Diluted
------------- ------------- ------------- -------------
1998 1,126,504,245 1,139,231,632 1,128,826,525 1,145,347,028
1997 1,131,053,603 1,148,485,338 1,130,755,483 1,149,803,450
<Fg> Year to date earnings per share do not equal the sum of quarterly
earnings per share due to changes in average share calculations.
14
<PAGE>
<TABLE>
E. I. DU PONT DE NEMOURS AND COMPANY AND CONSOLIDATED SUBSIDIARIES
<CAPTION>
CONSOLIDATED INDUSTRY SEGMENT INFORMATION - Three Months Ended Year Ended
CONTINUING OPERATIONS December 31 December 31
- ------------------------------------------------------------------------------------------------------------------
(Dollars in millions, except per share) 1998 1997 1998 1997
- -----------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C>
SALES
- -----
Chemicals ........................................... $ 1,019 $ 1,084 $ 4,113 $ 4,267
Fibers .............................................. 1,716 1,932 7,281 7,680
Polymers ............................................ 1,725 1,724 6,858 6,830
Life Sciences ....................................... 890 461 3,355 2,518
Diversified Businesses .............................. 749 702 3,160 2,794
------- ------- ------- -------
Total ........................................... $ 6,099 $ 5,903 $24,767 $24,089
======= ======= ======= =======
AFTER-TAX OPERATING INCOME (LOSS)<Fa><Fb>
- -----------------------------------------
Chemicals ........................................... $ 172 $ 163 $ 647 <Fc> $ 590
Fibers .............................................. 193 260 631 962
Polymers ............................................ 256 227 898 911
Life Sciences ....................................... 46<Fd> (516)<Fe> (429)<Fd> (790)<Fe>
Diversified Businesses .............................. 178<Ff> 18 <Fg> 193 <Ff> (15)<Fg>
------- ------- ------- -------
ATOI from Continuing Operations ................. 845 152 1,940 1,658
Interest and Other Corporate Expenses, Net of Tax ... (64) (81) (292) (226)
------- ------- ------- -------
NET INCOME FROM CONTINUING OPERATIONS
BEFORE EXTRAORDINARY ITEM ......................... $ 781 $ 71 $ 1,648 $ 1,432
======= ======= ======= =======
<FN>
<Fa> Prior periods have been restated to reflect the petroleum business as
discontinued operations.
<Fb> Total year 1998 includes a charge of $256 resulting from a Company-wide
productivity improvement initiative (Chemicals - $51; Fibers - $82;
Polymers - $27; Life Sciences - $16; and Diversified Businesses - $80)
and charges of $130 within the Fibers segment attributable to employee
separation costs and the shutdown of related manufacturing facilities.
<Fc> Includes a $36 gain on the sale of Hydrogen Peroxide assets, in addition
to the charge in Note (b).
<Fd> Purchased in-process research and development represents the value
assigned in a purchase business combination to research and development
projects of the acquired business that were commenced but not yet
completed at the date of acquisition, for which technological feasibility
has not been established and which have no alternative future use in
research and development activities or otherwise.
</TABLE>
15
<PAGE>
[FN]
NOTES TO CONSOLIDATED INDUSTRY SEGMENT - (CONT'D)
- --------------------------------------
The fourth quarter 1998 includes a benefit, based on revision of
preliminary purchase price allocations to purchased in-process research
and development, of $46 in conjunction with the purchase of Merck's 50%
interest in The DuPont Merck Pharmaceutical Company (DuPont Merck) and,
in addition, a $54 impairment write-down to fair value of certain
Pharmaceutical assets.
In addition to the charge indicated in Note (b), total year 1998 includes
a charge of $799 related to purchased in-process research and development
for DuPont Pharmaceuticals, the $54 impairment write-down indicated
above, and a $60 charge to increase, based on revision of preliminary
purchase price allocations, the $500 charge taken in the fourth quarter
1997, of the purchase price allocation related to purchased in-process
research and development in conjunction with the purchase of Protein
Technologies International (PTI).
<Fe> Includes a charge of $553 ($53 for a charge, based on revision of
preliminary purchase price allocations to purchased in-process research
and development, in conjunction with the purchase of 20 percent interest
in Pioneer Hi-Bred International, Inc. (Pioneer) and $500 for the
purchase of PTI) for the fourth quarter 1997, and $1,403 ($903 for
Pioneer and $500 for PTI) for the total year 1997, related to purchased
in-process research and development. The charges associated with Pioneer
and PTI were not tax effected because these transactions were stock
rather than asset purchases. Also includes a charge of $62 for the
quarter and the year associated with the "Benlate" 50 DF fungicide
recall. In addition, the year includes a benefit of $72 from the
Company's equity interest in the gain on the sale by DuPont Merck (now
DuPont Pharmaceuticals) of its generic and multisource product lines.
<Ff> Fourth quarter includes a gain of $121 on the sale by the Company of
substantially all of its remaining interest in CONSOL Energy Inc., a
50/50 coal operations joint venture, and a charge of $14, based on
revision of preliminary purchase price allocations to purchased
in-process research and development, in conjunction with the purchase of
the ICI polyester businesses.
In addition to the charge indicated in Note (b), total year 1998 includes
a charge of $123, based on revision of preliminary purchase price
allocations to purchased in-process research and development, in
conjunction with the purchase of the ICI polyester businesses, offset by
the $121 gain on the sale of substantially all of the Company's remaining
interest in CONSOL Energy Inc.
<Fg> Includes a fourth quarter charge of $63, based on preliminary allocations
of purchase price to purchased in-process research and development, in
conjunction with the purchase of the ICI polyester businesses. Total
year also includes $220 associated with exiting the Company's global
graphics arts films and offset printing plates businesses.
16
<PAGE>
<TABLE>
E. I. DU PONT DE NEMOURS AND COMPANY AND CONSOLIDATED SUBSIDIARIES
<CAPTION>
CONSOLIDATED INDUSTRY SEGMENT INFORMATION
EXCLUDING IMPACT OF NONRECURRING ITEMS - Three Months Ended Year Ended
CONTINUING OPERATIONS December 31 December 31
- ------------------------------------------------------------------------------------------------------------------
(Dollars in millions, except per share) 1998 1997 1998 1997
- -----------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C>
AFTER-TAX OPERATING INCOME
- --------------------------
Chemicals ........................................... $ 172 $ 163 $ 662 $ 590
Fibers .............................................. 193 260 843 962
Polymers ............................................ 256 227 925 911
Life Sciences ....................................... 54 99 500 603
Diversified Businesses .............................. 71 81 275 268
------ ------ ------ ------
ATOI from Continuing Operations ................... 746 830 3,205 3,334
Interest and Other Corporate
Expenses, Net of Tax .............................. (64) (81) (292) (226)
------ ------ ------ ------
NET INCOME FROM CONTINUING OPERATIONS
BEFORE EXTRAORDINARY ITEM ......................... $ 682 $ 749 $2,913 $3,108
====== ====== ====== ======
</TABLE>
17
